Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endocan, VEGF and TNF-alpha Levels in Periodontal Disease and After Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02750956
Recruitment Status : Completed
First Posted : April 26, 2016
Last Update Posted : April 26, 2016
Sponsor:
Information provided by (Responsible Party):
ÇİĞDEM COŞKUN TÜRER, Bulent Ecevit University

Brief Summary:
The primer aim of the study was to determine serum and gingival crevicular fluid (GCF) endocan levels in periodontal diseases pathogenesis supported with vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) levels.

Condition or disease Intervention/treatment
Periodontal Disease Procedure: Non-surgical periodontal treatment

Detailed Description:
The study consist of three groups: periodontally healthy individuals (group 1; n = 20), individuals with generalized chronic periodontitis (group 2; n = 20), the same patients with chronic periodontitis after they had been treated with scaling and root planing (SRP) were considered as Group 3. Clinical measurements were recorded; GCF and serum samples were obtained from each participant before and 6 weeks after therapy. Endocan, VEGF-A and TNF-α levels were measured by enzyme-linked immunosorbent assay.

Layout table for study information
Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A and Tumor Necrosis Factor Alpha Levels
Study Start Date : June 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : March 2016

Group/Cohort Intervention/treatment
Group 1
Periodontal healthy individuals
Group 2
Patients with chronic periodontitis
Procedure: Non-surgical periodontal treatment
Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Group 3
the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
Procedure: Non-surgical periodontal treatment
Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis




Primary Outcome Measures :
  1. Endocan levels [ Time Frame: 6 weeks ]
    Change after periodontal treatment


Secondary Outcome Measures :
  1. VEGF levels [ Time Frame: 6 weeks ]
    Change after periodontal treatment

  2. TNF-alpha levels [ Time Frame: 6 weeks ]
    Change after periodontal treatment


Biospecimen Retention:   Samples Without DNA
Gingival crevicular fluid and Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Total of 40 individuals
Criteria

Group 1 Inclusion Criteria:

  • No bone and attachment loss,
  • GI=0, PPD≤3mm, CAL≤3mm
  • Systematically healthy patients

Group 2 Inclusion Criteria:

  • GI>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically.
  • Systematically healthy patients

Exclusion Criteria:

  • Aggressive Periodontitis,
  • Oral pathologies,
  • Patients with any other systemic diseases,
  • Pregnant women and those in the lactation period,
  • Patients with smoking habit and taking medication
  • Patients received periodontal therapy in last 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750956


Sponsors and Collaborators
Bulent Ecevit University
Investigators
Layout table for investigator information
Principal Investigator: ÇİĞDEM COŞKUN TÜRER BULENT ECEVIT UNIVERSITY FACULTY OF DENTISTRY DEPARTMENT OF PERIODONTOLOGY

Layout table for additonal information
Responsible Party: ÇİĞDEM COŞKUN TÜRER, Dr., Bulent Ecevit University
ClinicalTrials.gov Identifier: NCT02750956     History of Changes
Other Study ID Numbers: Endocan
First Posted: April 26, 2016    Key Record Dates
Last Update Posted: April 26, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by ÇİĞDEM COŞKUN TÜRER, Bulent Ecevit University:
endocan protein
VEGF A
TNF-alpha
after treatment

Additional relevant MeSH terms:
Layout table for MeSH terms
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs